Previously we reported a new series of highly defective herpes simplex virus type 1 (HSV-1) vectors that were functionally devoid of all viral immediately early (IE) genes, resulting in virtual absence of viral gene expression. Nevertheless, a reporter gene cassette inserted into the vector flanked by boundary elements from the viral latency locus showed high, persistent reporter gene activity in non-neuronal cells while an independent expression cassette inserted into a deleted ICP4 locus remained almost silent. In contrast to non-neuronal cells, we show here that the ICP4 locus cassette permitted robust reporter gene expression in a diversity of neurons following stereotactic injection of different rat brain regions; transgene expression ...
This study shows that an ICP4-replication-deficient herpes simplex virus containing the Moloney muri...
The delivery of recombinant genes into the brain is becom-ing an increasingly important strategy for...
A key factor for developing gene therapy strategies for neurological disorders is the availability o...
Previously we reported a new series of highly defective herpes simplex virus type 1 (HSV-1) vectors ...
The herpes simplex virus type 1 (HSV-1) latency associated promoter (LAP) has been shown to sustain ...
The ability of herpes simplex virus (HSV) to establish lifelong latency in neurons suggests that HSV...
The natural history of Herpes simplex virus type 1 (HSV-1) infection in humans suggests its potentia...
Herpes simplex virus (HSV) is a neurotropic DNA virus. The viral genome is large (152 kb), and many ...
Although attenuated retroviral vectors provide an acceptable gene transfer vector system for many ce...
Manipulation of gene expression in developing or in mature central nervous systems (CNS) holds a pro...
Genetic diseases arise from the aberrant expression of genes. These disorders can potentially be tre...
Overview summary Development of suitable vectors for transfer of genes to the central nervous system...
Herpes simplex virus type 1 (HSV-1) vectors have now been developed and enable the efficient deliver...
Herpes Simplex Virus (HSV) is potentially an ideal vector for gene therapy in the peripheral nervous...
Neurodegenerative diseases (NDs) have a profound impact on human health worldwide and their incidenc...
This study shows that an ICP4-replication-deficient herpes simplex virus containing the Moloney muri...
The delivery of recombinant genes into the brain is becom-ing an increasingly important strategy for...
A key factor for developing gene therapy strategies for neurological disorders is the availability o...
Previously we reported a new series of highly defective herpes simplex virus type 1 (HSV-1) vectors ...
The herpes simplex virus type 1 (HSV-1) latency associated promoter (LAP) has been shown to sustain ...
The ability of herpes simplex virus (HSV) to establish lifelong latency in neurons suggests that HSV...
The natural history of Herpes simplex virus type 1 (HSV-1) infection in humans suggests its potentia...
Herpes simplex virus (HSV) is a neurotropic DNA virus. The viral genome is large (152 kb), and many ...
Although attenuated retroviral vectors provide an acceptable gene transfer vector system for many ce...
Manipulation of gene expression in developing or in mature central nervous systems (CNS) holds a pro...
Genetic diseases arise from the aberrant expression of genes. These disorders can potentially be tre...
Overview summary Development of suitable vectors for transfer of genes to the central nervous system...
Herpes simplex virus type 1 (HSV-1) vectors have now been developed and enable the efficient deliver...
Herpes Simplex Virus (HSV) is potentially an ideal vector for gene therapy in the peripheral nervous...
Neurodegenerative diseases (NDs) have a profound impact on human health worldwide and their incidenc...
This study shows that an ICP4-replication-deficient herpes simplex virus containing the Moloney muri...
The delivery of recombinant genes into the brain is becom-ing an increasingly important strategy for...
A key factor for developing gene therapy strategies for neurological disorders is the availability o...